testing / Shutterstock.com
4 March 2025NewsBig PharmaMuireann Bolger

Teva can’t revive Orange book inhaler battle at Fed Circ

Federal Circuit says only patents claiming the active ingredient of a drug are eligible for listing | Injunction against Teva temporarily paused in January pending the appeal court’s decision to review.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 January 2025   Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.